Antios Therapeutics
Mendham, US · Founded 2018 · Delaware corporation · 21 known investors
Find your way into Antios Therapeutics
12 people in our graph share verified history with the Antios Therapeutics team — schools, employers, funds. One of them is your warm intro.
Nicole Vitullounlockedknows Douglas Mayers · together at Antios Therapeutics (overlapped)
×5knows the team · via Penn State University
knows the team · via US Navy Reserves
×2knows the team · via Idenix Pharmaceuticals
knows the team · via Boehringer Ingelheim Pharmaceuticals
×2knows the team · via Cocrystal Pharma
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.
Founders & leadership
Antios Therapeutics was founded in 2018 by Gregory Mayes.
GM
Gregory MayesFounder
DM
Douglas MayersinChief Medical Officer and Cofounder2018–2023
TA
Tamra AdamsinChief Financial Officer2021–2023
AD
Abel De La RosaNamed on SEC filing
Board
IR
BR
Benjamin RovinskiBoard director
PH
Patrick HigginsBoard director
SM
Scott MorensteinBoard director
DC
David CannerBoard director
Investors · 21
Aisling CapitalNew York
Altium CapitalNew York
Avego BioScience CapitalAlpharetta
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Amzak HealthreportedNew York
Delos CapitalreportedCambridge
Domain AssociatesreportedPrinceton · $200K – $15M
Domain PartnersreportedPrinceton
GRA VenturereportedGeorgia
Granite Point Capitalreported
LifeSci Venture PartnersreportedNew York
Lumira Venturesreported · 2 sourcesToronto · $1M – $10M
RA CapitalreportedBoston
Sixty Degree CapitalreportedNorth York
Soleus CapitalreportedGreenwich
Also in the syndicate · 6
CAM CapitalFonds de solidarité des travailleurs du Québec (FTQ)GordonMD Global InvestmentsleadHeartland Healthcare CapitalPontifaxThe EPIQ Capital Grouplead
Reported raises · per SEC filings
Form D private placements$126.4M disclosed across 4 rounds · 2018–2021
▶$75MraisedNov 2021 · 35 investors · PharmaceuticalsRule 506(b)
▶$75MraisedNov 2021 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin RovinskiDirector
- Scott MorensteinDirector
- Tamra AdamsExecutive Officer
- Craig GordonDirector
- Gregory MayesExecutive Officer, Director
- Abel De La RosaDirector
- Douglas MayersExecutive Officer
- Patrick HigginsDirector
- Iyona RajkomarDirector
- Offering amount
- $86M
- Amount sold
- $75M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$32MraisedApr 2021 · 29 investors · PharmaceuticalsRule 506(b)
▶$32MraisedApr 2021 · 29 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Abel De La RosaDirector
- Iyona RajkomarDirector
- Douglas MayersExecutive Officer
- Benjamin RovinskiDirector
- Patrick HigginsDirector
- Tamra AdamsExecutive Officer
- Scott MorensteinDirector
- David CannerDirector
- Gregory MayesExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $32M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$4.4MraisedAug 2020 · 9 investors · BiotechnologyRule 506(b)
▶$4.4MraisedAug 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Idean MarvastyExecutive Officer
- Douglas MayersExecutive Officer
- Abel De La RosaExecutive Officer, Director
- Nicole VitulloDirector
- Henry Lin ChenDirector
- Benjamin RovinskiDirector
- Scott MorensteinDirector
- Offering amount
- $5M
- Amount sold
- $4.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15MraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
▶$15MraisedDec 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin RovinskiDirector
- Abel De La RosaExecutive Officer, Director
- Nicole VitulioDirector
- Henry Lin ChenDirector
- Douglas MayersExecutive Officer
- Scott MorensteinDirector
- Idean MarvastyExecutive Officer
- Offering amount
- $25M
- Amount sold
- $15M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Antios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Antios Therapeutics do?
- Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.
- Who founded Antios Therapeutics?
- Antios Therapeutics was founded by Gregory Mayes in 2018.
- Who are Antios Therapeutics's investors?
- Antios Therapeutics's investors include Aisling Capital, Altium Capital, Avego BioScience Capital, Pontifax Venture Capital, Amzak Health, Delos Capital, Domain Associates, Domain Partners and 7 more.
- How much funding has Antios Therapeutics raised?
- Antios Therapeutics has disclosed $126.4M raised across 4 rounds.
- Where is Antios Therapeutics headquartered?
- Antios Therapeutics is headquartered in Mendham, US.